# 1. Financial Performance ## A. Key Figures * Revenue: **₹1,812 Mn** Q3 FY26 (+4%) * EBITDA: INR474 million Q3 (26% margin) · INR484 million normalized (27% margin) * **PAT:** **₹168 million** normalized Q3 (9% margin) * **Cash Recovery:** **₹130 Cr+** government dues recovered in Q3 · **₹100 Cr+** YoY improvement in collections ## B. Revenue Growth * **Modest Top-Line Uptick:** Q3 revenue growth was modest, impacted by seasonality, festive periods, and temporary project pauses to clear receivables. * **Divergent Business Trends:** Base business (ex-B2C, ex-Rajasthan) shows **higher-teens annualized growth potential**, while core operations (excluding retail) faced structural headwinds with low single-digit or negative growth. * **Growth Outlook Intact:** Despite near-term revenue challenges, management affirms the long-term growth trajectory remains unchanged, with acceleration expected in coming quarters. ## C. EBITDA & PAT * **Resilient Margins:** EBITDA margin held firm at 26–27% despite absorption of project readiness and staffing costs, underscoring operating leverage and cost discipline. * **Sustained Profitability:** Company remains profitably scaled since inception, achieving structural profitability even while pricing services **50–70% below market rates** in a regulated environment. * **Rapid Scale Achievement:** Reached current scale in just over 14 years—far faster than peers (20–40 years)—validating operating model and execution strength. ## D. Cash Flow * **Material Cash Flow Improvement:** Seasonally soft quarter offset by **over ₹130 Cr in government receivables recovered**, significantly strengthening liquidity. * **Working Capital Discipline:** Collections improved by **over ₹100 Cr YoY**, reflecting maturing execution and tighter working capital controls. --- # 2. Revenue Mix & Segments ## A. Key Figures * **B2C Revenue Contribution:** **~8%** of group revenue (9MFY26) (+8x YoY retail growth) * **B2B Revenue Shift:** **34%** of revenue (Q1 FY26) vs. 90% (Q1 FY25) ## B. Pathology & Radiology * **Balanced Core, Shifting Future Mix:** Pathology and radiology currently contribute near **50-50** to revenue, with both showing strong organic growth; however, **pathology is set to become dominant (65–70%)** post ramp-up of large government projects in Rajasthan and Maharashtra. * **Durable Competitive Edge:** Krsnaa’s diagnostics platform is **uniquely differentiated and difficult to replicate**, supported by organic expansion—unlike peers relying on acquisitions—creating high entry barriers and long-term institutional value. * **Strategic Clinical Expansion:** Beyond core diagnostics, the company is deepening its footprint in **cancer, cardiac, obesity, and gastro care** via over **100 subspecialized wellness packages**, enhancing patient engagement across the care continuum. ## C. B2C & B2B Split * **B2C Emerges as Strategic Growth Engine:** Retail diagnostics has scaled rapidly, now forming a **material second pillar** alongside PPP, driven by **8x YoY growth**, expanded touchpoints (+7% QoQ), and **24/7 service models** at competitive prices. * **B2B Reclassification, Not Contraction:** The sharp decline in B2B’s revenue share reflects **reclassification of certain contracts into PPP or retail**, not a strategic retreat; the company continues to pursue both channels, with primary investment focused on B2C scaling. ## D. PPP vs Retail * **Market Leadership in PPP Diagnostics:** Krsnaa is **India’s largest public-private partnership diagnostics platform**, positioned as a long-term infrastructure partner in national healthcare delivery, deploying equipment in district hospitals to improve rural access. --- # 3. Project Execution & Capacity ## A. Key Figures * **Rajasthan Project Revenue:** **₹200 Cr** annualized (FY '27) * **Apulki Hospital Revenue:** **₹20+ Cr** annual (mature, in 2–3 years) * ₹700 Cr deployed over 4.5 years (FY '19–'23) * **Retail Network:** **3,000+** touchpoints * **Labs & Collection Centers in Rajasthan:** **20 labs**, **300+ collection centers** operational ## B. Rajasthan Rollout * **Flagship PPP Execution:** Rajasthan project under active implementation with majority completion expected by Q4, though some satellite labs and collection centers may spill into Q1. * **Near-Term Margin Pressure:** Front-loaded expenses in Q4 likely to weigh on profitability, despite efforts to align revenue timing. * **Strategic Scale Advantage:** Krsnaa is the only company to deploy diagnostics across an entire state, reinforcing its scalable PPP execution capability. * **Growth Visibility Gap:** No major order wins in past 12 months outside Rajasthan, raising questions on near-term pipeline depth. ## C. Maharashtra Progress * **Revenue Ramp-Up Ahead:** Maharashtra radiology project under implementation with site clearances secured; revenue expected from Q4 onward, though MRI installations not yet inaugurated. * **Limited Pipeline Momentum:** No additional major orders beyond current projects, indicating a thin near-term execution pipeline. ## D. Lab & Center Expansion * **Integrated Care Expansion:** Apulki Hospital (150 beds) now operational, marking strategic entry into tertiary care; additional hospitals under construction to support long-term growth. * **Capital Discipline:** Deployment now clearance-driven, especially in PPPs, reflecting heightened caution post-Rajasthan learnings. * **Network-Led Strategy:** Focus on selective, sustainable B2C network expansion—leveraging largest PAN-India radiology footprint—to drive low-churn, long-term scale. --- # 4. Network & Utilization ## A. Key Figures * **Network Scale:** **18** states/UTs · **190** CT/MRI centers · **4,000+** collection centers · **~140** pathology labs * **Patient Reach:** **81 Mn+** patients served to date · **4.6 Mn** patients in Q3 alone ## B. Geographic Reach * **National Leadership:** Krsnaa has built the **largest PAN-India radiology network**, establishing a high-entry-barrier platform with durable competitive advantages in a capital-intensive sector. * **Expansion Runway:** Current presence in **over 100 districts** (out of 730+) indicates a **6x geographic expansion capacity** in underserved areas. * **Urban Penetration:** Operations extend into **municipal corporations**, broadening reach beyond district-level infrastructure. ## C. Asset Utilization * **Operational Efficiency:** Higher utilization of advanced radiology modalities and **supply chain optimization** have significantly reduced installation timelines and equipment downtime, boosting asset productivity. ## D. Patient Volume * **Scale Impact:** Rapid scale achieved in **just over 14 years**, positioning Krsnaa as one of India’s most impactful diagnostic platforms. * **Organic Growth Driver:** Existing centers show **strong organic volume growth**, fueled by rising awareness of accessible, high-quality, 24/7 diagnostic services. * **Seasonality Dynamics:** **Pathology volumes are primarily affected by seasonality**, while **external events like cyclones impact both pathology and radiology equally**. --- # 5. Cost & Margin Trends ## A. Key Figures *No significant quantitative financial metrics (e.g., revenue, EBITDA, margin %, growth rates) were provided in the input to populate this section.* ## B. Gross Margin Pressure * **Capital-Intensive Model:** Krsnaa operates a **radiology-led, PPP-based platform** requiring upfront equipment investments nearly **5x higher** than pathology-led peers, creating structural cost differentials. * **Temporary Margin Headwinds:** Q3 margin pressure stemmed from **cost absorption in Rajasthan rollout**—a timing-related issue with no structural impact, expected to reverse as operations scale. * **Seasonal & Operational Drags:** Performance weighed down by **seasonally soft volumes** and **temporary pauses** to recover government receivables, both transient factors. * **Mix-Driven Margin Risk:** Growing pathology revenue share poses a slight gross margin headwind, as it carries **lower margins than radiology**, though offset by scale and efficiency efforts. * **Durable Asset Base:** Core radiology equipment (X-ray, CT, MRI) has **long asset lives** (up to 40 years for MRI magnets) with stable technology; upgrades driven by software, not hardware replacement. ## C. Employee Cost Impact * **Elevated Manpower Costs:** Rajasthan PPP expansion is driving **higher employee costs** due to staffing needs across collection centers, with **lodging and rent expenses** adding near-term pressure in Q4. * **Margin Management Mindset:** Management aims to **maintain current margin levels** during rollout years, prioritizing stability over expansion amid large-scale project execution. ## D. Cost Optimization * **Efficiency Gains:** Focus on **manpower deployment, asset utilization, and procurement** has improved operating performance, supported by **technology-led automation** in reporting, billing, and monitoring. * **AI & Software Leverage:** **AI and software enhancements** (e.g., 3D modeling, image clarity) are boosting radiologist efficiency and outcomes, with **negligible obsolescence risk**. * **Low-Cost Marketing Approach:** Marketing remains **low-spending and calculated**, now incorporating **Instagram-based campaigns** for retail expansion. * **Favorable Input Cost Trends:** **GST changes** have improved control over **consumable costs**, while better collections are expected to reduce **working capital-related interest expenses**. * **Proactive Cost Calibration:** Management is **strategically aligning personnel and processes** to minimize financial impact of new projects and maintain **stable consolidated gross margins**. --- # 6. Risks & Government Factors ## A. Key Figures * **Receivables Collections:** ₹133 Cr across PPP projects (+₹100 Cr YoY) * **Himachal Pradesh Collections:** ₹40 Cr received in Q3 ## B. Receivables Collection * **Improved Cash Flow Visibility:** Significant YoY increase in collections reflects stronger government payment momentum, with substantial receipts from Himachal Pradesh and recent confirmations from Karnataka. * **Disciplined Collections Strategy:** Temporary suspension of operations in Rajasthan and Karnataka underscores a strict, principle-based approach to receivables management, reinforcing Krsnaa’s reputation as the only consistent collector in the PPP space. * **Accreditation as Competitive Edge:** Unmatched quality infrastructure with **49 NABH-accredited radiology centers**, **57 NABL-accredited labs**, and pioneering **CAP and ACR recognitions** strengthens trust and negotiating power with state governments. ## C. Tender Timing * **Resilience to Tender Cycles:** No major contracts nearing expiry, and the company emphasizes continuous growth potential independent of tender timing, supported by embedded pricing in existing PPP agreements. * **Favorable Policy Pricing Tailwinds:** New tenders expected to align with updated CGHS rates, potentially enabling **better pricing realization**; current contracts remain unaffected. * **Selective PPP Rollout:** Expansion remains gradual and state-driven, dependent on government hospital identification and budget allocation, limiting near-term saturation risk. ## D. Policy Integration * **Structural Demand-Supply Gap:** PPP model directly addresses underfunded public diagnostic infrastructure, creating a durable growth runway in preventive care and affordable access. * **Growth Moderation Due to Policy Hurdles:** Near-term delays in revenue ramp-up attributed to **ABHA integration challenges**, project pauses, and government-imposed caps—transient bottlenecks rather than model flaws. * **Long-Term Moat Despite Regulation:** Sustained EBITDA and PAT positivity since inception, even while delivering services at **50% to 70% below market rates**, highlights operational resilience and pricing discipline within a highly regulated ecosystem. * **Positive Signal from National Health Hubs:** Government’s plan for **5 new healthcare hubs** aligns with Krsnaa’s expansion strategy and could catalyze medical tourism and diagnostic demand. --- # 7. Guidance & Outlook ## A. Breakeven Timeline * **Breakeven Target Reaffirmed:** Management maintains **RPL is on track to reach breakeven by year-end** with no changes to the timeline. ## B. Growth Visibility * **Resilient Model with Long-Term Visibility:** Platform underpinned by **long-term PPP contracts** offering **up to 60 years of revenue visibility**, particularly in oncology and cardiac diagnostics, reinforcing structural durability. * **Near-Term Ramp-Up Expected:** **Revenue recognition and meaningful volume ramp from the Rajasthan project** anticipated in the coming quarter and next fiscal year, driving clear growth momentum. * **Operational Headwinds Transitory:** Q3 softness attributed to **one-off seasonality and delayed receivables**, with **Q4 recovery expected** due to government budget cycles and improved collections. * **Scalability Remains Intact:** Despite current challenges, management asserts the **full economic potential of Krsnaa’s platform remains untapped**, with strong operating leverage set to emerge over time. * **Strategic Expansion Focus:** Growth strategy centered on **scalability, unit economics, regional deepening**, and potential participation in new **PPP-based healthcare hubs**.